These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 1327312)
21. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization. Harenberg J Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409 [TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight heparins in clinical practice. Hunt D South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394 [TBL] [Abstract][Full Text] [Related]
23. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Ofosu FA Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312 [TBL] [Abstract][Full Text] [Related]
24. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Hirsh J; Raschke R Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472 [TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparins: a decade with the new class of antithrombotic agents. Bounameaux H Vasa; 1994; 23(1):3-9. PubMed ID: 8154171 [TBL] [Abstract][Full Text] [Related]
27. Are the available low-molecular-weight heparin preparations the same? Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734 [TBL] [Abstract][Full Text] [Related]
28. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102 [TBL] [Abstract][Full Text] [Related]
29. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue. Fareed J; Haas S; Sasahar A Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730 [TBL] [Abstract][Full Text] [Related]
30. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. Tapson VF; Hull RD Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540 [TBL] [Abstract][Full Text] [Related]
36. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278 [TBL] [Abstract][Full Text] [Related]
37. Safety profile of different low-molecular weight heparins used at therapeutic dose. Gouin-Thibault I; Pautas E; Siguret V Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242 [TBL] [Abstract][Full Text] [Related]
38. [State of the art: low-molecular-weight heparin and beyond]. Cimminiello C; Casali G; Vitali L Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343 [TBL] [Abstract][Full Text] [Related]
39. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Samama MM; Bara L; Gerotziafas GT Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358 [TBL] [Abstract][Full Text] [Related]
40. [Low molecular weight heparins]. Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; Fernandez G; De Seze O; Deharo E; Vairel EG; Quilichini R Ann Pharm Fr; 1989; 47(3):109-16. PubMed ID: 2561387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]